v3.25.3
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Total revenue $ 2,534.7 $ 2,465.8 $ 7,611.2 $ 7,221.2
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 674.4 638.7 1,908.7 1,726.9
Research and development 436.1 516.2 1,269.2 1,467.0
Acquired in-process research and development, upfront and milestone expense 2.1 26.5 249.4 42.5
Selling, general and administrative 594.8 588.4 1,751.1 1,723.7
Amortization and impairment of acquired intangible assets 135.7 130.3 378.4 295.5
Collaboration profit sharing/(loss reimbursement) 87.2 69.3 220.3 197.3
Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) 5.6 23.8 28.4 23.8
Restructuring charges 7.4 6.8 42.0 24.9
Gain on sale of priority review voucher, net 0.0 0.0 0.0 (88.6)
Other (income) expense, net 34.1 14.8 151.2 193.7
Total cost and expense 1,977.4 2,014.8 5,998.7 5,606.7
Income before income tax (benefit) expense 557.3 451.0 1,612.5 1,614.5
Income tax (benefit) expense 90.8 62.5 270.7 249.0
Net income attributable to Biogen Inc. $ 466.5 $ 388.5 $ 1,341.8 $ 1,365.5
Net income per share:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) $ 3.18 $ 2.67 $ 9.16 $ 9.38
Diluted earnings per share attributable to Biogen Inc. (in USD per share) $ 3.17 $ 2.66 $ 9.14 $ 9.35
Weighted-average shares used in calculating:        
Basic earnings per share attributable to Biogen Inc. (in USD per share) 146,600 145,700 146,400 145,500
Diluted earnings per share attributable to Biogen Inc. (in USD per share) 147,100 146,100 146,800 146,000
Product revenue, net        
Total revenue $ 1,846.9 $ 1,769.4 $ 5,452.1 $ 5,380.9
Revenue from anti-CD20 therapeutic programs        
Total revenue 493.9 446.2 1,339.4 1,284.7
Alzheimer's collaboration revenue        
Total revenue 42.7 18.6 130.6 33.2
Contract manufacturing, royalty and other revenue        
Total revenue $ 151.2 $ 231.6 $ 689.1 $ 522.4